FDA OKs expanded use for Gilead's Epclusa to include patients co-infected with HIV

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

The FDA approves updated labeling for Gilead Sciences' (NASDAQ:GILD) HCV med Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) to include the use in patients co-infected with HIV.

The FDA OK'd the drug to treat adults with genotype 1-6 chronic HCV infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin, in June 2016.

Subscribe for full text news in your inbox